Glycopeptide Antibiotics Market Synopsis:
Glycopeptide Antibiotics Market Size Was Valued at USD 2.86 Billion in 2023, and is Projected to Reach USD 4.31 Billion by 2032, Growing at a CAGR of 4.20% From 2024-2032.
Glycopeptide antibiotics are those antibiotics which are being employed carefully, but effectively to attack some of the major resistant bacteria infections such as methicillin-resistant Staphylococcus aureus (MRSA). These antibiotics act by disrupting the formation of the layer surrounding bacterial cells with the result that bacteria cannot grow and dies off. Some of the most common glycopeptide antibiotics are the vancomycin and teicoplanin. These antibiotics are probed more for critical infection cases because of the strength and the likelihood of the antibiotic becoming ineffective. The glycopeptide antibiotics market involves the marketing and distribution of these drugs used in many diseases fields, settings, such as hospitals, clinics, and others.
The major factors that fuels the glycopeptide antibiotics market are the increasing prevalence of bacterial infections and specifically those which are resistant to multiple antibiotics. The rise in hospital-acquired infections HAIs and antibiotic discharged pathogens such as MRSA has compounded the need for glycopeptides one of the strongest drugs for discharging such pathogens. These antibiotics are manufactured by different companies and used in hospitals and all other health facility in treating severe infections. Glycopeptide antibiotics have continued to garner a stable market around the world with new formulations and dosing strategies that increase the efficacy and safety. Therefore, as antibiotic resistance continues to be observed, the market is anticipated to grow because of need for better antibiotics.
In addition, the changing trend for the development of advanced health care infrastructure particularly in growing economy has propelled the growth of the market. Health care improvements and rising consciousness about ABR are also compelling analysts to use glycopeptide antibiotics in clinical practices. Also, growth in the number of research efforts targeting at enhancing the existing drugs or developing other drugs in this category has equally reinforced market potential. However, the market, nevertheless, experiences some challenges in relation to the cost of glycopeptide antibiotics which may not be easily affordable in the low-income countries.
.webp)
Glycopeptide Antibiotics Market Trend Analysis:
The Rise of Antibiotic Resistance and Its Impact on Glycopeptide Demand
-
The growing problem of antibiotic resistance around the world is one of the more important factors that shape the glycopeptide antibiotics market. With new bacterial strains emerging all over the world and that of showing resistance to standard antibiotics, the need for stronger drugs such as glycopeptide antibiotics is expected to rise. This is now being compounded by irrational and improper use of antibiotics in human and veterinary medicine and in animal production systems. Especially, methicillin-resistant Staphylococcus aureus (MRSA) has stimulated the consumption of glycopeptides because these drugs can be effective against such strains.
- Due to the obvious need for effective management of diseases associated with AMR, healthcare systems globally are beginning to prioritize this problem and are extending the use of glycopeptide antibiotics within their control programs. This trend has created new glycopeptide formulations, different dosages, and administration techniques – thus propelling the market. Also, the focus of stewardship programmes in hospitals and other healthcare centres seeks to reduce the usage of antibiotics, including glycopeptides, in disease combating making them core assets in the management of infections.
Expansion in Emerging Markets
-
An excellent driving force for the glycopeptide antibiotics market is the growth of the healthcare sector in the new markets. Asia-Pacific, Latin America and many African nations at various stages of development of their health care systems are facing constantly increasing burden of infectious diseases and as such a continuous need for good antimicrobial treatments.
- For instance, increased levels of resistance to these antibiotics prevalent in these regions increase the need for new antibiotics including glycopeptides. Increased middle-income group people and relative improvement in healthcare facilities resulting to patients’ admission and outpatient services in these regions will propel the demand for effective antibiotics. These markets are being addressed by firms through the localization of production, distribution networks and partnership with healthcare stakeholders in the affected markets to ensure adequate supply of glycopeptide antibiotics. On the same note, the healthcare reformation by governments of emerging markets that offer easy access to essential medicines is considered to bolster the glycopeptide antibiotics market in the near future.
Glycopeptide Antibiotics Market Segment Analysis:
Glycopeptide Antibiotics Market is Segmented on the basis of Drug Type, Application, End User, and Region
By Drug Type, Vancomycin segment is expected to dominate the market during the forecast period
-
The glycopeptide antibiotics are primarily classified by drug type and of this, the most recognizable and often used antibiotic is vancomycin. Vancomycin has been one of the mainstay treatment options for serious bacterial infections attributable to MRSA and other resistant Gram-positive bacteria. Its effectiveness, non-c Edge Centrality against Gram-positive organisms and long standing at the market proves it as the best medicine for critical diseases including; bloodstream infections, pneumonia and skin disorders. Therefore constant use of vancomycin in formulations and altering dosage regimes substantially guarantee its domination of the glycopeptide antibiotics.
- Teicoplanin, which is also a major drug of this class, has other valuable properties, including a more prolonged half-life and a single day administration, thus the drug is more effective to treat ambulatory patients and chronical infections. Currently it is being used in the European and Asian countries for the indications closer to vancomycin such as MRSA infection. In the “Other” segment, new glycopeptides and adjusted formulations are categorized; the development of which is resultative to the increasing resistance patterns and overall therapeutic efficacy. These are for instance, dalbavancin and oritavancin, which have higher potency and more flexible dosing schedule, in an effort to meet new needs of the market.
By Application, Pneumonia segment expected to held the largest share
-
The use of the glycopeptide antibiotics is very important as it is used to treat severe and resistant infections whereby Hospital Acquired Infections (HAIs) are major indication. A HAIs itself, are commonly identifiable in healthcare sectors based on invasive methods as well as duration of hospitalization where surgical site infections, catheter-associated bloodstream infections, and ventilator-associated pneumonia inclusive. Vancomycin is often selected to be used as first-line therapeutic agents in these situations because of its activity against multidrug resistant Gram-positive cocci including MRSA. The increasing rates of HAIs around the world due to the growth of the aged population and the enhanced hospitalization have vested significance to glycopeptides regarding its effort to curb those severe complications.
- Also, glycopeptide antibiotics used extensively in the management of other serious infections including skin and skin structure infections, pneumonia, and septicaemia. Glycopeptides are used for the treatment of skin and soft tissue infections especially where the bacteria is known to be resistant. They also find their usefulness in the management of both CAP and HAP from resistant organisms. Another major area of use for glycopeptides is bloodstream infections although any infection that involves a resistant bacterial strain is a potent killer if untreated. These applications render glycopeptide antibiotics as precious tool in present day infection prevention and management.
Glycopeptide Antibiotics Market Regional Insights:
North America is Expected to Dominate the Market Over the Forecast period
-
In 2023, the region wise analysis of glycopeptide antibiotics found that North America is still the leading region representing high market share across the global. Currently, the largest shareholder in this market is the United States, thanks to well-developed healthcare systems, high healthcare and top rates of bacterial infections, including those that cause resistant pathogens, MRSA. Market analysis reveals that around 40% to 45% share of glycopeptide antibiotics market was owned by North America in 2023.
- This dominance is due to the increasing medical research and development activities and high standards of regulations governing antibiotic using countries in the region. Some of the largest pharmaceutical companies are in the region with major focus on research and marketing of glycopeptide antibiotics including Vancomycin. The rising prevalence of Hospital Acquired Infections and the growing focus towards implementing antimicrobial stewardship program augment the robust market requirement of glycopeptides in North America. The population has easy access to medical insurance and there exist well developed delivery networks especially for drugs and medical supplies.
Active Key Players in the Glycopeptide Antibiotics Market:
- Amgen (USA)
- Astellas Pharma (Japan)
- AstraZeneca (UK)
- Baxter International (USA)
- Bayer AG (Germany)
- Cipla Limited (India)
- Hunan Huakang Pharmaceutical Co., Ltd. (China)
- Merck & Co., Inc. (USA)
- Mylan (USA)
- Novartis AG (Switzerland)
- Pfizer Inc. (USA)
- Roche Holding AG (Switzerland)
- Sanofi (France)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Zoetis Inc. (USA)
- Other Active Players
|
Glycopeptide Antibiotics Market |
|||
|
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
|
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 2.86 Billion |
|
Forecast Period 2024-32 CAGR: |
4.20% |
Market Size in 2032: |
USD 4.31 Billion |
|
Segments Covered: |
By Drug Type |
|
|
|
By Application |
|
||
|
By End User |
|
||
|
By Region |
|
||
|
Key Market Drivers: |
|
||
|
Key Market Restraints: |
|
||
|
Key Opportunities: |
|
||
|
Companies Covered in the report: |
|
||
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: Glycopeptide Antibiotics Market by Drug Type
4.1 Glycopeptide Antibiotics Market Snapshot and Growth Engine
4.2 Glycopeptide Antibiotics Market Overview
4.3 Vancomycin
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.3.3 Key Market Trends, Growth Factors and Opportunities
4.3.4 Vancomycin: Geographic Segmentation Analysis
4.4 Teicoplanin
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.4.3 Key Market Trends, Growth Factors and Opportunities
4.4.4 Teicoplanin: Geographic Segmentation Analysis
4.5 Others
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.5.3 Key Market Trends, Growth Factors and Opportunities
4.5.4 Others: Geographic Segmentation Analysis
Chapter 5: Glycopeptide Antibiotics Market by Application
5.1 Glycopeptide Antibiotics Market Snapshot and Growth Engine
5.2 Glycopeptide Antibiotics Market Overview
5.3 Hospital-Acquired Infections (HAIs)
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Hospital-Acquired Infections (HAIs): Geographic Segmentation Analysis
5.4 Skin and Soft Tissue Infections
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Skin and Soft Tissue Infections: Geographic Segmentation Analysis
5.5 Pneumonia
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Pneumonia: Geographic Segmentation Analysis
5.6 Bloodstream Infections
5.6.1 Introduction and Market Overview
5.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.6.3 Key Market Trends, Growth Factors and Opportunities
5.6.4 Bloodstream Infections: Geographic Segmentation Analysis
5.7 Others
5.7.1 Introduction and Market Overview
5.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.7.3 Key Market Trends, Growth Factors and Opportunities
5.7.4 Others: Geographic Segmentation Analysis
Chapter 6: Glycopeptide Antibiotics Market by End User
6.1 Glycopeptide Antibiotics Market Snapshot and Growth Engine
6.2 Glycopeptide Antibiotics Market Overview
6.3 Hospitals
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Hospitals: Geographic Segmentation Analysis
6.4 Clinics
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 Clinics: Geographic Segmentation Analysis
6.5 Home Healthcare
6.5.1 Introduction and Market Overview
6.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
6.5.3 Key Market Trends, Growth Factors and Opportunities
6.5.4 Home Healthcare: Geographic Segmentation Analysis
6.6 Others
6.6.1 Introduction and Market Overview
6.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
6.6.3 Key Market Trends, Growth Factors and Opportunities
6.6.4 Others: Geographic Segmentation Analysis
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Benchmarking
7.1.2 Glycopeptide Antibiotics Market Share by Manufacturer (2023)
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Mergers and Acquisitions
7.2 AMGEN (USA)
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Role of the Company in the Market
7.2.5 Sustainability and Social Responsibility
7.2.6 Operating Business Segments
7.2.7 Product Portfolio
7.2.8 Business Performance
7.2.9 Key Strategic Moves and Recent Developments
7.2.10 SWOT Analysis
7.3 ASTELLAS PHARMA (JAPAN)
7.4 ASTRAZENECA (UK)
7.5 BAXTER INTERNATIONAL (USA)
7.6 BAYER AG (GERMANY)
7.7 CIPLA LIMITED (INDIA)
7.8 HUNAN HUAKANG PHARMACEUTICAL CO. LTD. (CHINA)
7.9 MERCK & CO. INC. (USA)
7.10 MYLAN (USA)
7.11 NOVARTIS AG (SWITZERLAND)
7.12 PFIZER INC. (USA)
7.13 ROCHE HOLDING AG (SWITZERLAND)
7.14 SANOFI (FRANCE)
7.15 TEVA PHARMACEUTICAL INDUSTRIES LTD. (ISRAEL)
7.16 ZOETIS INC. (USA)
7.17 OTHER ACTIVE PLAYERS
Chapter 8: Global Glycopeptide Antibiotics Market By Region
8.1 Overview
8.2. North America Glycopeptide Antibiotics Market
8.2.1 Key Market Trends, Growth Factors and Opportunities
8.2.2 Top Key Companies
8.2.3 Historic and Forecasted Market Size by Segments
8.2.4 Historic and Forecasted Market Size By Drug Type
8.2.4.1 Vancomycin
8.2.4.2 Teicoplanin
8.2.4.3 Others
8.2.5 Historic and Forecasted Market Size By Application
8.2.5.1 Hospital-Acquired Infections (HAIs)
8.2.5.2 Skin and Soft Tissue Infections
8.2.5.3 Pneumonia
8.2.5.4 Bloodstream Infections
8.2.5.5 Others
8.2.6 Historic and Forecasted Market Size By End User
8.2.6.1 Hospitals
8.2.6.2 Clinics
8.2.6.3 Home Healthcare
8.2.6.4 Others
8.2.7 Historic and Forecast Market Size by Country
8.2.7.1 US
8.2.7.2 Canada
8.2.7.3 Mexico
8.3. Eastern Europe Glycopeptide Antibiotics Market
8.3.1 Key Market Trends, Growth Factors and Opportunities
8.3.2 Top Key Companies
8.3.3 Historic and Forecasted Market Size by Segments
8.3.4 Historic and Forecasted Market Size By Drug Type
8.3.4.1 Vancomycin
8.3.4.2 Teicoplanin
8.3.4.3 Others
8.3.5 Historic and Forecasted Market Size By Application
8.3.5.1 Hospital-Acquired Infections (HAIs)
8.3.5.2 Skin and Soft Tissue Infections
8.3.5.3 Pneumonia
8.3.5.4 Bloodstream Infections
8.3.5.5 Others
8.3.6 Historic and Forecasted Market Size By End User
8.3.6.1 Hospitals
8.3.6.2 Clinics
8.3.6.3 Home Healthcare
8.3.6.4 Others
8.3.7 Historic and Forecast Market Size by Country
8.3.7.1 Russia
8.3.7.2 Bulgaria
8.3.7.3 The Czech Republic
8.3.7.4 Hungary
8.3.7.5 Poland
8.3.7.6 Romania
8.3.7.7 Rest of Eastern Europe
8.4. Western Europe Glycopeptide Antibiotics Market
8.4.1 Key Market Trends, Growth Factors and Opportunities
8.4.2 Top Key Companies
8.4.3 Historic and Forecasted Market Size by Segments
8.4.4 Historic and Forecasted Market Size By Drug Type
8.4.4.1 Vancomycin
8.4.4.2 Teicoplanin
8.4.4.3 Others
8.4.5 Historic and Forecasted Market Size By Application
8.4.5.1 Hospital-Acquired Infections (HAIs)
8.4.5.2 Skin and Soft Tissue Infections
8.4.5.3 Pneumonia
8.4.5.4 Bloodstream Infections
8.4.5.5 Others
8.4.6 Historic and Forecasted Market Size By End User
8.4.6.1 Hospitals
8.4.6.2 Clinics
8.4.6.3 Home Healthcare
8.4.6.4 Others
8.4.7 Historic and Forecast Market Size by Country
8.4.7.1 Germany
8.4.7.2 UK
8.4.7.3 France
8.4.7.4 The Netherlands
8.4.7.5 Italy
8.4.7.6 Spain
8.4.7.7 Rest of Western Europe
8.5. Asia Pacific Glycopeptide Antibiotics Market
8.5.1 Key Market Trends, Growth Factors and Opportunities
8.5.2 Top Key Companies
8.5.3 Historic and Forecasted Market Size by Segments
8.5.4 Historic and Forecasted Market Size By Drug Type
8.5.4.1 Vancomycin
8.5.4.2 Teicoplanin
8.5.4.3 Others
8.5.5 Historic and Forecasted Market Size By Application
8.5.5.1 Hospital-Acquired Infections (HAIs)
8.5.5.2 Skin and Soft Tissue Infections
8.5.5.3 Pneumonia
8.5.5.4 Bloodstream Infections
8.5.5.5 Others
8.5.6 Historic and Forecasted Market Size By End User
8.5.6.1 Hospitals
8.5.6.2 Clinics
8.5.6.3 Home Healthcare
8.5.6.4 Others
8.5.7 Historic and Forecast Market Size by Country
8.5.7.1 China
8.5.7.2 India
8.5.7.3 Japan
8.5.7.4 South Korea
8.5.7.5 Malaysia
8.5.7.6 Thailand
8.5.7.7 Vietnam
8.5.7.8 The Philippines
8.5.7.9 Australia
8.5.7.10 New Zealand
8.5.7.11 Rest of APAC
8.6. Middle East & Africa Glycopeptide Antibiotics Market
8.6.1 Key Market Trends, Growth Factors and Opportunities
8.6.2 Top Key Companies
8.6.3 Historic and Forecasted Market Size by Segments
8.6.4 Historic and Forecasted Market Size By Drug Type
8.6.4.1 Vancomycin
8.6.4.2 Teicoplanin
8.6.4.3 Others
8.6.5 Historic and Forecasted Market Size By Application
8.6.5.1 Hospital-Acquired Infections (HAIs)
8.6.5.2 Skin and Soft Tissue Infections
8.6.5.3 Pneumonia
8.6.5.4 Bloodstream Infections
8.6.5.5 Others
8.6.6 Historic and Forecasted Market Size By End User
8.6.6.1 Hospitals
8.6.6.2 Clinics
8.6.6.3 Home Healthcare
8.6.6.4 Others
8.6.7 Historic and Forecast Market Size by Country
8.6.7.1 Turkiye
8.6.7.2 Bahrain
8.6.7.3 Kuwait
8.6.7.4 Saudi Arabia
8.6.7.5 Qatar
8.6.7.6 UAE
8.6.7.7 Israel
8.6.7.8 South Africa
8.7. South America Glycopeptide Antibiotics Market
8.7.1 Key Market Trends, Growth Factors and Opportunities
8.7.2 Top Key Companies
8.7.3 Historic and Forecasted Market Size by Segments
8.7.4 Historic and Forecasted Market Size By Drug Type
8.7.4.1 Vancomycin
8.7.4.2 Teicoplanin
8.7.4.3 Others
8.7.5 Historic and Forecasted Market Size By Application
8.7.5.1 Hospital-Acquired Infections (HAIs)
8.7.5.2 Skin and Soft Tissue Infections
8.7.5.3 Pneumonia
8.7.5.4 Bloodstream Infections
8.7.5.5 Others
8.7.6 Historic and Forecasted Market Size By End User
8.7.6.1 Hospitals
8.7.6.2 Clinics
8.7.6.3 Home Healthcare
8.7.6.4 Others
8.7.7 Historic and Forecast Market Size by Country
8.7.7.1 Brazil
8.7.7.2 Argentina
8.7.7.3 Rest of SA
Chapter 9 Analyst Viewpoint and Conclusion
9.1 Recommendations and Concluding Analysis
9.2 Potential Market Strategies
Chapter 10 Research Methodology
10.1 Research Process
10.2 Primary Research
10.3 Secondary Research
|
Glycopeptide Antibiotics Market |
|||
|
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
|
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 2.86 Billion |
|
Forecast Period 2024-32 CAGR: |
4.20% |
Market Size in 2032: |
USD 4.31 Billion |
|
Segments Covered: |
By Drug Type |
|
|
|
By Application |
|
||
|
By End User |
|
||
|
By Region |
|
||
|
Key Market Drivers: |
|
||
|
Key Market Restraints: |
|
||
|
Key Opportunities: |
|
||
|
Companies Covered in the report: |
|
||
